Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 4Papillomavirus Infections 2Uterine Diseases 1Uterine Cervical Neoplasms 1Neoplasms 1Genital Diseases, Female 1

Interventions

niraparib 2anlotinib 2Robotic Surgical Procedures 2Paclitaxel 2Carboplatin 2Bevacizumab 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2temsirolimus 1olaparib 1carboprost tromethamine 1Watchful Waiting 1Transurethral Resection of Prostate 1Trabectedin 1Preoperative Care 1Pregnancy Tests 1Postoperative Care 1Ocoxin 1Laparoscopy 1Intraoperative Care 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Human Papillomavirus DNA Tests 1GX-188 vaccine 1Filgrastim 1Diffusion 1Dexamethasone 1Connor-Davidson Resilience Scale 1Colposcopy 1CP protocol 1Biopsy 1Acetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Diseases, Female × GX-188 vaccine × Clear all
NCT02139267 2017-07-12

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Genexine, Inc.

Phase 2 Completed
72 enrolled
Gynecologic

Uterine Cervical Dysplasia, Genital Diseases, Female, Neoplasms, Uterine Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡